← All trials
NCT06318169
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 13, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Feb 28, 2029
- First posted
- Mar 19, 2024
- Last posted
- Nov 5, 2024
- Enrollment
- 1050
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- 89bio Ltd.Lead sponsor
- 89bio Ltd.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.